HIV associated and post-transplantation lymphomas;HIV-assoziierte lymphome und posttransplantationslymphome

Onkologe

Volumn 12, Issue 7, 2006, Pages 641-650

  Trappe, R ^a   Oertel, S ^a   Riess, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; HIV; PTLD; Rituximab; Transplantation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CIDOFOVIR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ARTICLE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; SURVIVAL RATE;

EID: 33745890917     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-006-1057-z     Document Type: Article

References (23)

1. Benkerrou M, Jais JP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 9: 3137-3147
2. Choquet S, Leblond V, Jaeger U et al. (2003) Efficacy of CHOP Regimen as First LineTherapy in Post-transplantation Lymphoproliferative Disorders (PT-LD). A Retrospective Study on 25 Cases. Blood 11: abstract #3897
3. Comoli P, Maccario R, Locatelli F et al. (2005) Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 6: 1415-1422
4. Grefer J, Oertel SH, Hummel M (2001) B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliverative disorder (PT-LPD). Blood 6 [Suppl 242b]
5. Haddad E, Paczesny S, Leblond V et al. (2001) Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 6: 1590-1597
6. Ho M, Jaffe R, Miller G et al.(1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 4: 719-727
7. Kaplan LD, Lee JY, Ambinder RF et al. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 5: 1538-1543
8. Kaplan LD, Straus DJ, Testa MA et al. (1997) Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 23: 1641-1648
9. Rishnan A, Molina A, Zaia J et al. (2005) Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2: 874-878
10. Leblond V, Sutton L, Dorent R et al. (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 4: 961-968
11. Levine AM (2000) Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 4: 442-453
12. Little RF, Pittaluga S, Grant N et al. (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 12: 4653-4659
13. Mentzer SJ, Perrine SP, Faller DV (2001) Epstein Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 3: 177-185
14. Oertel S, Trappe RU, Zeiderl K et al. (2006) Epstein-Barr virus DNA in blood samples of adults with Post-Transplant Lymphoproliferative Disease does not correlate with clinical course. Ann Hematol. Epub ahead of print
15. Oertel SH, Anagnostopoulos I, Hummel MW et al. (2002) Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 4: 1120-1123
16. Oertel SH, Papp-Vary M, Anagnostopoulos I et al. (2003) Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 5: 830-835
17. Oertel SH, Verschuuren E, Reinke P et al. (2005) Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). Am J Transplant 12: 2901-2906
18. Ratner L, Lee J, Tang S et al. (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 8: 2171-2178
19. Sparano JA, Lee S, Chen MG et al. (2004) Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HlV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology GroupTrial (E1494). J Clin Oncol 8: 1491-1500
20. Spina M, Jaeger U, Sparano JA et al. (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 5: 1891-1897
21. Spina M, Sparano JA, Jaeger U et al. (2003) Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 1: 137-138
22. Suryanarayan K, Natkunam Y, Berry G et al. (2001) Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for post-transplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 7: 452-455
23. Trappe R, Oertel SH, Choquet S et al. (2005) Sequential Treatment With The anti-CD 20 Antibody Rituximab And CHOP+GCSF Chemotherapy In Patients With Post-transplant Lymphoproliferative Disorder (PTLD): First Results Of A Multicenter Phase II Study. Blood 11: 274a